{"title":"[摘要]内分泌治疗与ER/PR联合治疗","authors":"H. Mackay","doi":"10.1158/1557-3265.ENDOMET20-IA006","DOIUrl":null,"url":null,"abstract":"Endocrine therapy is the “original” targeted therapy in endometrial cancer (EC). Despite over 60 years experience with this treatment modality we have yet to answer some key questions including which women derive benefit and how do we identify them? Despite a high proportion of ECs being ER and/or PR positive, endocrine therapy is only associated with modest benefit. Greater understanding of ER and PR biology may help identify patient populations who will derive benefit and assist in optimizing this approach. Favourable toxicity profiles and multiple pathway interactions suggest the potential for combining endocrine and other targeted agents. We discuss the preliminary data and hypothesize on potential strategies to accelerate the pace of development in this area. Citation Format: Helen J. MacKay. Endocrine therapy and ER/PR combinations [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr IA006.","PeriodicalId":289246,"journal":{"name":"Targeted Therapeutics","volume":"77 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract IA006: Endocrine therapy and ER/PR combinations\",\"authors\":\"H. Mackay\",\"doi\":\"10.1158/1557-3265.ENDOMET20-IA006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Endocrine therapy is the “original” targeted therapy in endometrial cancer (EC). Despite over 60 years experience with this treatment modality we have yet to answer some key questions including which women derive benefit and how do we identify them? Despite a high proportion of ECs being ER and/or PR positive, endocrine therapy is only associated with modest benefit. Greater understanding of ER and PR biology may help identify patient populations who will derive benefit and assist in optimizing this approach. Favourable toxicity profiles and multiple pathway interactions suggest the potential for combining endocrine and other targeted agents. We discuss the preliminary data and hypothesize on potential strategies to accelerate the pace of development in this area. Citation Format: Helen J. MacKay. Endocrine therapy and ER/PR combinations [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr IA006.\",\"PeriodicalId\":289246,\"journal\":{\"name\":\"Targeted Therapeutics\",\"volume\":\"77 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Targeted Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1557-3265.ENDOMET20-IA006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Targeted Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1557-3265.ENDOMET20-IA006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
内分泌治疗是子宫内膜癌(EC)的“原始”靶向治疗。尽管这种治疗方式有60多年的经验，但我们还没有回答一些关键问题，包括哪些妇女从中受益，我们如何识别她们?尽管ECs ER和/或PR阳性的比例很高，但内分泌治疗仅与适度的益处相关。对ER和PR生物学的深入了解可能有助于确定受益的患者群体，并有助于优化该方法。有利的毒性特征和多途径的相互作用表明了将内分泌和其他靶向药物联合使用的潜力。我们讨论了初步数据，并提出了加快这一领域发展步伐的潜在策略。引文格式:Helen J. MacKay。内分泌治疗与ER/PR联合治疗[摘要]。AACR虚拟特别会议论文集:子宫内膜癌:新生物学驱动研究和治疗;2020年11月9-10日。费城(PA): AACR;临床肿瘤杂志，2021;27(3 -增刊):摘要/ Abstract
Abstract IA006: Endocrine therapy and ER/PR combinations
Endocrine therapy is the “original” targeted therapy in endometrial cancer (EC). Despite over 60 years experience with this treatment modality we have yet to answer some key questions including which women derive benefit and how do we identify them? Despite a high proportion of ECs being ER and/or PR positive, endocrine therapy is only associated with modest benefit. Greater understanding of ER and PR biology may help identify patient populations who will derive benefit and assist in optimizing this approach. Favourable toxicity profiles and multiple pathway interactions suggest the potential for combining endocrine and other targeted agents. We discuss the preliminary data and hypothesize on potential strategies to accelerate the pace of development in this area. Citation Format: Helen J. MacKay. Endocrine therapy and ER/PR combinations [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr IA006.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
